View Older Stories View More Recent Stories

Sep 12, 2024 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 28, 2024 04:30PM PTC Therapeutics to Participate at Upcoming Investor Conferences
Aug 8, 2024 04:01PM PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Jul 30, 2024 08:01AM PTC Therapeutics (PTCT) Submits Sepiapterin NDA Submission to FDA
Jul 30, 2024 08:00AM PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
Jul 25, 2024 04:30PM PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
Jun 28, 2024 06:00AM PTC Therapeutics (PTCT) Receives Negative CHMP Opinion on Translarna
Jun 28, 2024 06:00AM CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
Jun 21, 2024 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 20, 2024 06:31AM PTC Therapeutics (PTCT) Reports Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects
Jun 20, 2024 06:30AM Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
May 29, 2024 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conference
May 28, 2024 08:30AM PTC Therapeutics Announces Validation of Sepiapterin European MAA
May 20, 2024 07:01AM PTC Therapeutics (PTCT) Reports EU Commission Returns Translarna Opinion to CHMP For Re-evaluation
May 20, 2024 07:00AM PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
May 14, 2024 07:30AM PTC Therapeutics (PTCT) Announces FDA Acceptance and Priority Review of the BLA for Upstaza
May 14, 2024 07:30AM PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
May 2, 2024 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
Apr 25, 2024 04:05PM PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Apr 23, 2024 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 11, 2024 08:00AM PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Mar 28, 2024 08:32AM PTC Therapeutics (PTCT) Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
Mar 28, 2024 08:30AM PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
Mar 19, 2024 07:31AM PTC Therapeutics (PTCT) Provides Regulatory Updates
Mar 19, 2024 07:30AM PTC Therapeutics Provides Key Regulatory Updates
Feb 29, 2024 04:05PM PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 27, 2024 05:20PM PTC Therapeutics to Participate at Upcoming Investor Conferences
Feb 22, 2024 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15, 2024 08:00AM PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Jan 25, 2024 04:07PM PTC Therapeutics (PTCT) Reports Negative CHMP Opinion for Renewal of Conditional Marketing Authorization for Translarna
Jan 25, 2024 04:05PM CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
Jan 8, 2024 09:26AM PTC Therapeutics (PTCT) Provides an Update on Commercial Progress and R&D Pipeline
Jan 8, 2024 09:26AM PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
Jan 3, 2024 08:00AM PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Dec 14, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2023 04:16PM PTC Therapeutics (PTCT) Provides Updates on Translarna Regulatory Activities
Dec 5, 2023 04:15PM PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
Nov 3, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2023 04:05PM PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
Oct 19, 2023 08:03AM PTC Therapeutics (PTCT) Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5B
Oct 19, 2023 08:00AM PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
Oct 16, 2023 04:30PM PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 
Sep 28, 2023 04:32PM PTC Therapeutics (PTCT) Announces 25% Workforce Cut
Sep 28, 2023 04:30PM PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
Sep 15, 2023 06:00AM PTC Therapeutics' (PTCT) Translarna Receives Negative CHMP Opinion
Sep 15, 2023 06:00AM CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
Sep 7, 2023 08:00AM PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
Aug 30, 2023 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
Aug 3, 2023 04:01PM PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
Jul 21, 2023 09:30AM PTC Therapeutics (PTCT) Announces CHMP Recommends Evrysdi for Babies Under Two Months Old with Spinal Muscular Atrophy
View More Recent Stories View Older Stories